Details of the Drug Combinations

General Information of This Drug (ID: DMCA7FN)

Drug Name

Exatecan DMCA7FN

Synonyms

Exatecan mesylate; DX-8951; DX-8951a; DX-8951f; UM-1; UM-2

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 3	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

2 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Exatecan + Panobinostat	DCYYLUQ	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
Exatecan + Ruxolitinib	DCW090B	Ruxolitinib	Hodgkin lymphoma (Cell Line: L-1236)	[3]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00023972) Gemcitabine With or Without Exatecan Mesylate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer. U.S. National Institutes of Health.
2	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
3	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.